This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
healthcare: Archive
UNH vs. ELV: Which Managed Care Stock Has the Edge Today?
by Rajshree Sipani
Elevance Health is edging past UnitedHealth as Carelon's growth, strategic exits and a cheaper valuation shape a stronger near-term setup.
artificial-intelligence dental finance healthcare hospitals insurance insurance-premium medical smart-health
The Longevity Shift: Healthcare REITs to Benefit From Global Aging
by Urmimala Biswas
WELL, VTR, CTRE and OHI are tapping the longevity economy as aging populations drive rising demand for senior housing, skilled nursing and long-term care real estate.
finance healthcare medical medical-devices
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
by Urmimala Biswas
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
artificial-intelligence earnings-growth earnings-outlook healthcare medical medical-devices
Tempus AI Near $75 Target? Valuation, Upside and Risks
by Urmimala Biswas
Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.
artificial-intelligence healthcare medical medical-devices
Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?
by Urmimala Biswas
Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.
artificial-intelligence earnings-report healthcare medical medical-devices valuation
Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook
by Urmimala Biswas
Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.
artificial-intelligence earnings-report healthcare medical medical-devices
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
by Urmimala Biswas
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.
healthcare medical medical-devices oncology-screening
Is UnitedHealth's Valuation Dip & Divestment Diet a Real Buy Window?
by Kaibalya Pravo Dey
UNH trades below its five-year median P/E as it navigates margin pressure, membership declines and strategic divestments.
healthcare hmo insurance insurance-premium medical
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVS? (Revised)
by Rajshree Sipani
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
healthcare hmo insurance medical smart-health
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVH?
by Rajshree Sipani
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
healthcare hmo insurance medical smart-health